Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) EPS (Weighted Average and Diluted) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with $0.26 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 160.47% to $0.26 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.13 through Dec 2025, up 32.34% year-over-year, with the annual reading at -$1.11 for FY2025, 33.13% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.26 at Orchestra BioMed Holdings, up from -$0.4 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.26 in Q4 2025, with the low at -$0.77 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.41, with a median of -$0.42 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 160.47% in 2025, while the deepest fall reached 28.95% in 2025.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at -$0.44 in 2022, then increased by 15.91% to -$0.37 in 2023, then decreased by 16.22% to -$0.43 in 2024, then skyrocketed by 160.47% to $0.26 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $0.26, -$0.4, and -$0.5 for Q4 2025, Q3 2025, and Q2 2025 respectively.